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Does Pharmacogenetics Play a Role in the Treatment  
of Type II Diabetes Mellitus? 
Lucas N VanEmelen, PA-S 
Abstract 
Introduction 
 Type 2 diabetes mellitus is a worldwide epidemic 
 
 
• A multifactorial, heterogeneous metabolic disorder 
characterized by hyperglycemia and elevated insulin resistance. 
• Results from both genetic and environmental factors.   
• Multiple genes that are associated with the risk of developing 
diabetes 
• Patients are often treated with more than one medication.  
• Genetic testing could be employed to predict treatment outcome 
 
Pharmacogenetic 
• Studies focused on diabetic medications and a role of common 
drug-metabolizing enzymes and drug-transporters variants in 
therapy outcomes.  
 
 
 
 
 
 
 
• The future of promoting safe and cost-effective individualized 
diabetes treatment, pharmacogenomics has a great potential to 
complement current efforts to optimize treatment of diabetes 
and lead towards its effectiveness and personalized care. 
Research Questions 
Applicability to Clinical 
Practice 
thanks . . .  
• Multiple genes that are associated with the risk of developing 
diabetes or the risk of diabetes complications have been 
identified by candidate gene analysis and genome wide 
scanning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Pharmacogenetics can lead to the personalized treatment of type 
II diabetes. 
 
• Known genes that cause diabetes have been reviewed and 
genotyping of an individual with diabetes could direct providers 
to accurate choices for diabetic therapy 
 
• The genome-wide association studies (GWAS) have facilitated 
a substantial and rapid rise in the number of confirmed genetic 
susceptibility variants for type 2 diabetes.  
 
• The result of Type 2 diabetes is many long-term adverse 
consequences. Chronic hyperglycemia results in microvascular 
complications such as retinopathy, nephropathy and neuropathy, 
and macrovascular complications such as cardiovascular 
disease, stroke and peripheral vascular disease.   
 
• The goal of Type 2 diabetes treatment in men and non-pregnant 
women is to decrease periods of poor glycemic control and 
maintain hemoglobin (HbA1c) levels of less than 7%. Lowering 
glucose to near non-diabetic levels in Type 2 diabetes patients 
has been shown to reduce the risk of microvascular 
complications. 
 
 
 
• There are several genes associated with diabetes and 
hyperglycemic medications with more studies being published 
every day.  
 
• More evidence and studies will need to be conducted to see if 
pharmacogenomics will play a role in the future treatment of 
type 2 diabetes mellitus. 
 
 
• Type 2 diabetes mellitus (T2DM) is a disease commonly 
presented in the family practice setting.  Current therapies 
include one or multiple medications. Until recently, providers 
have used algorithms and medical expertise to control T2DM. 
•  Pharmacogenomics is a branch of pharmacology dealing with 
genetic variation on a medication response in an individual 
patient to discover medication compatibility, efficacy or 
toxicity.  
• Analysis of genetic factors are still being discovered; however, 
this growing field may change the way medications are being 
prescribed for diabetes. This analysis investigated if 
pharmacogenetics is a useful tool for prescribing diabetic 
medications to T2DM patients. It was found that health care 
providers will be able to maximize therapy to those currently 
taking diabetic medication.  
• The goal would be to personalize the treatment of T2DM by 
ensuring compatibility of the medication being prescribed. 
Although many genes have been implicated in the response to 
diabetic medications, the findings indicate that health care 
providers can improve the quality of care of patients taking 
diabetic medications by choosing the correct diabetic 
medication for the individual patient. 
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• T2DM patients are often treated with more than one drug, 
including oral diabetic drugs.  
• If genetic testing could be employed to predict treatment 
outcome, appropriate measures could be taken to treat T2DM 
more efficiently. 
Biguanide 
• In 2011, Zhou et al. found that common variants near the ataxia 
telangiectasia mutated (ATM) are associated with glycemic response to 
metformin in type 2 diabetes.  Metformin is recommended as a first line 
therapy for type 2 diabetes in most international guidelines. 
• Becker et al. 2009, examined the genetic variation in the organic cation 
transporter that is associated with metformin response in patients with 
diabetes mellitus.  
• Thiazolinediones 
• Aquilante et al. 2013, examined the influence of CYP2C8*2 on the 
pharmacokinetics of pioglitazone in healthy African American volunteers. 
The data in the study suggested a potential functional significance and 
merits further study. 
Meglitinides 
• Huang et al. 2010, examined IGF2BP2 variations influence repaglinide 
response and risk of type 2 diabetes in the Chinese population. Patients 
with the rs4402960 GT+TT genotypes exhibited an enhanced effect of 
repaglinide treatment on postprandial serum insulin compared with GG 
genotype subjects. 
Sulfonylureas 
• Sulfonylureas are metabolized in the liver by CYP2C9. 
• The major allele of this gene is CYP2C9*1. 
• There are also two variants with reduced function, CYP2C9 *2 and 
CYP2C9*3, which are associated with decreased clearance in the liver with 
better effect of this medication  
 
 
 
 
 
• Diabetes has increased disabilities and an enormous cost to the 
health care system while reducing the quality of life and life 
expectancy.  
 
• Strategies for personalized approaches to glycemic management 
discussed represents a personalized management approach to 
lowering blood glucose concentrations.  The recent studies and 
advances in genetic and other molecular technologies creates a 
strong interest in more personalized approaches to diabetes 
management which will be the most effective for the patient.  
• I would like to express sincere appreciation to my family 
especially my wife, Jan VanEmelen, Dr. Kuntz and the UND 
PA school staff for all the support, patience, and time spent 
supporting this project. I would also like to thank my 
preceptor Dr. Don Edgerly for the inspiration and 
confidence. 
Statement of the Problem 
• Since diabetes is not currently a curable disease, clinical 
guidance suggests the ability to tailor medications to the 
patients’ needs may be the best compound the future of 
diabetes. 
• Developing new medications is a lengthy process. The 
development of new medications which can take 10-20 years to 
develop and receive approval. Utilizing medications already in 
use to detect compatibility to each individual patient is still 
being developed.  
• Multiple genes associated with the risk of developing diabetes 
have been identified by gene analysis and genome scanning. 
•  Markers together with clinical data, pharmacogenetics and 
other methods lead to the consideration of diabetes care being 
treated by genetic make-up of a patient.   
Discussion 
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